

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use TissueBlue 0.025% safely and effectively. See full prescribing information for TissueBlue 0.025%.

**TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025%  
For Intraocular Ophthalmic Administration  
Initial U.S. Approval: 2019**

-----INDICATIONS AND USAGE-----

TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is a disclosing agent indicated to selectively stain the internal limiting membrane (ILM). (1)

-----DOSAGE AND ADMINISTRATION-----

Inject TissueBlue 0.025% directly in a Balanced Salt Solution (BSS)-filled vitreous cavity. (2)  
Excess TissueBlue should be removed from the vitreous cavity. (2)

-----DOSAGE FORMS AND STRENGTHS-----

TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is supplied in 2.25 mL syringes filled to a volume of 0.5 mL. (3)

-----CONTRAINDICATIONS-----

None (4)

-----WARNINGS AND PRECAUTIONS-----

Excessive staining: Excess TissueBlue 0.025% should be removed from the eye immediately after staining. (5.1)  
Use of the syringe: Make sure the plunger moves smoothly before injecting the solution. (5.2)

-----ADVERSE REACTIONS-----

Adverse reactions that have been reported in procedures that included the use of TissueBlue 0.025% have often been associated with the surgical procedure. The complications include retinal (retinal break, tear, hemorrhage, and detachment and cataracts. (6)

**To report SUSPECTED ADVERSE REACTIONS, contact Dutch Ophthalmic, USA at 1-800-75-DUTCH or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch)**

Revised: 12/2019

**FULL PRESCRIBING INFORMATION: CONTENTS\***

- 1 INDICATIONS AND USAGE**
- 2 DOSAGE AND ADMINISTRATION**
- 3 DOSAGE FORMS AND STRENGTHS**
- 4 CONTRAINDICATIONS**
- 5 WARNINGS AND PRECAUTIONS**
  - 5.1 Excessive Staining
  - 5.2 Use of the Syringe
- 6 ADVERSE REACTIONS**
- 8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

**11 DESCRIPTION**

**12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action

**13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**16 HOW SUPPLIED/STORAGE AND HANDLING**

\*Sections or subsections omitted from the full prescribing information are not listed.

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is indicated to selectively stain the internal limiting membrane (ILM).

### **2 DOSAGE AND ADMINISTRATION**

TissueBlue 0.025% is carefully injected into the Balanced Salt Solution (BSS)-filled vitreous cavity using a blunt cannula attached to the pre-filled syringe, without allowing the cannula to contact the retina or allowing TissueBlue to get under the retina. Sufficient staining is expected within a few seconds. Following staining, all excess dye should be removed from the vitreous cavity.

### **3 DOSAGE FORMS AND STRENGTHS**

TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is a clear, bright blue, single-dose ophthalmic solution supplied in 2.25 mL syringes pre-filled to a volume of 0.5 mL.

### **4 CONTRAINDICATIONS**

None

### **5 WARNINGS AND PRECAUTIONS**

#### **5.1 Excessive Staining**

Excess TissueBlue 0.025% should be removed from the eye immediately after staining.

#### **5.2 Use of the Syringe**

Make sure the plunger moves smoothly before injecting the solution. Do not use the product if the plunger does not move smoothly to prime the cannula.

### **6 ADVERSE REACTIONS**

Adverse reactions that have been reported in procedures that included the use of Brilliant Blue G Ophthalmic Solution have often been associated with the surgical procedure. These complications include retinal (retinal break, tear, hemorrhage, and detachment) and cataracts.

### **8 USE IN SPECIFIC POPULATIONS**

#### **8.1 Pregnancy**

##### Risk Summary

There are no available data on the use of TissueBlue 0.025% in pregnant women to inform a drug associated risk. Systemic absorption of TissueBlue 0.025% in humans is expected to be negligible following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures. Due to the negligible systemic exposure, it is not expected that maternal use of TissueBlue 0.025% will result in fetal exposure to the drug.

Adequate animal reproduction studies were not conducted with TissueBlue 0.025%.

#### **8.2 Lactation**

##### Risk Summary

No data are available regarding the presence of Brilliant Blue G in human milk after intraocular administration of TissueBlue 0.025%, or the effects on the breastfed infant or the effects on milk production. However, breastfeeding is not expected to result

**U.S. Food and Drug Administration**

Silver Spring, MD 20993

[www.fda.gov](http://www.fda.gov)

in exposure of the child to Brilliant Blue G due to the expected negligible systemic exposure of BBG in humans following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures.

#### 8.4 Pediatric Use

The safety and effectiveness of TissueBlue 0.025% in pediatric patients has not been established.


#### 8.5 Geriatric Use

No overall differences in safety or effectiveness were observed between elderly and younger adult patients.

### 11 DESCRIPTION

TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is a sterile solution of BBG (a dye). Each mL of TissueBlue 0.025% contains BBG 0.25 mg, Polyethylene Glycol 40mg and Buffered Sodium Chloride solution (8.20 mg of sodium chloride, 3.10 mg sodium phosphate dibasic dodecahydrate, 0.30 mg sodium phosphate monobasic dihydrate, water for injection). The pH range of TissueBlue 0.025% Solution is between 7.3 and 7.6.

The drug substance BBG has the chemical name Brilliant Blue G, a molecular weight of 854.02 and has the following chemical structure:



Molecular formula:  $C_{47}H_{48}N_3NaO_7S_2$

### 12 CLINICAL PHARMACOLOGY

#### 12.1 Mechanism of Action

Brilliant Blue G has been shown to selectively stain the ILM, but not the epiretinal membrane nor the retina, making it easier to visualize the membrane for removal, although the exact mechanism of this selectivity has not been elucidated.

### 13 NONCLINICAL TOXICOLOGY

#### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies to evaluate the potential for carcinogenicity or impairment of fertility of TissueBlue 0.025% have not been conducted. Brilliant Blue G was not mutagenic in the Ames assay, the *in vitro* mouse lymphoma assay, or the *in vivo* rat micronucleus assay.

### 16 HOW SUPPLIED/STORAGE AND HANDLING

TissueBlue (Brilliant Blue G Ophthalmic Solution), 0.025% is supplied as 0.5 mL of Brilliant Blue G Ophthalmic Solution, 0.025% in a sterile, single-dose Luer Lok, 2.25 mL glass syringe, with a grey rubber plunger stopper and tip cap with polypropylene plunger rod in a pre-formed polypropylene blister pouch sealed with a Tyvek® lid.

NDC 68803-722-05 (One 0.5 mL syringe)

NDC 68803-722-25 (Carton of five 0.5 mL syringes)

TissueBlue 0.025% should be stored at 15°C to 25°C (59°F to 77°F). Protect from light, frost and moisture.

**Rx Only**

**U.S. Food and Drug Administration**

Silver Spring, MD 20993

[www.fda.gov](http://www.fda.gov)

*Distributed by:*

Dutch Ophthalmic, USA  
10 Continental Drive, Bldg 1  
Exeter, NH 03833, USA  
Phone: 800-75-DUTCH or 603-778-6929

Revision Date: 12/2019

Made in Germany

All trademarks are the property of their respective owners.